Home / Market News / $MRK
benzinga Corporate Catalyst Impact 65/100 ● positive

Merck Receives European Commission Approval For KEYTRUDA In Combination With Padcev For Adults With Resectable Muscle-Invasive Bladder Cancer

Oct 21, 2026, 10:47 AM UTC · Primary ticker $MRK

Merck announced European Commission approval for KEYTRUDA in combination with Padcev for resectable muscle-invasive bladder cancer, expanding its market reach in the EU. This approval provides a new chemotherapy-free treatment option for a broader patient population, regardless of cisplatin eligibility, and is based on strong Phase 3 trial results.

Merck has secured European Commission approval for its KEYTRUDA and Padcev combination therapy for resectable muscle-invasive bladder cancer. This is a significant development as it expands the treatment's availability to all 27 EU member states, Iceland, Liechtenstein, and Norway, and crucially, it applies to patients regardless of cisplatin eligibility, broadening the addressable market. The approval is based on robust Phase 3 trial data showing improved event-free survival and overall survival. In the short term, this provides a positive sentiment boost for Merck and its partners, while long-term, it solidifies KEYTRUDA's position in the oncology market and offers a new revenue stream as national reimbursement procedures are completed. For traders, this represents an opportunity to capitalize on Merck's expanding market share in a critical therapeutic area, with potential for increased sales and earnings.

$MRK positive Expanded market approval for key drug
$PFE positive Collaboration partner in KEYNOTE-B15 trial
$ALPMY positive Collaboration partner in KEYNOTE-B15 trial (Astellas Pharma)
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.